SILO PHARMA, INC. Selling, General and Administrative Expense
SILO PHARMA, INC. (SILO) reported Selling, General and Administrative Expense of $50.57 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2024-08-13
- SILO PHARMA, INC. selling, general and administrative expense for the quarter ending 2024-06-30 was $50.57K, a 78.85% decline year-over-year.
- SILO PHARMA, INC. selling, general and administrative expense for the quarter ending 2024-03-31 was $64.36K, a 0.93% decline year-over-year.
- SILO PHARMA, INC. selling, general and administrative expense for the quarter ending 2023-06-30 was $239.10K, a 822.52% increase year-over-year.
- SILO PHARMA, INC. selling, general and administrative expense for the quarter ending 2023-03-31 was $64.97K, a 76.42% increase year-over-year.
- SILO PHARMA, INC. selling, general and administrative expense for fiscal 2023 was $390.07K, a 71.64% increase from fiscal 2022.
- SILO PHARMA, INC. selling, general and administrative expense for fiscal 2022 was $227.26K, a 39.46% increase from fiscal 2021.
- SILO PHARMA, INC. selling, general and administrative expense for fiscal 2021 was $162.95K, a 224.66% increase from fiscal 2020.
- SILO PHARMA, INC. selling, general and administrative expense for fiscal 2020 was $50.19K.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|
| 2024-06-30 | $50.57K 10-Q · filed 2024-08-13 | $114.93K 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | $64.36K 10-Q · filed 2024-05-13 | |||||
| 2023-12-31 | $390.07K 10-K · filed 2024-03-25 | |||||
| 2023-06-30 | $239.10K 10-Q · filed 2024-08-13 | $304.07K 10-Q · filed 2024-08-13 | $408.24K derived: sum of 3 quarters · filed 2024-08-13 | $468.58K derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $64.97K 10-Q · filed 2024-05-13 | $169.14K derived: sum of 2 quarters · filed 2024-05-13 | $229.48K derived: sum of 3 quarters · filed 2024-05-13 | $255.40K derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $104.17K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $164.52K derived: sum of 2 quarters · filed 2024-03-25 | $190.43K derived: sum of 3 quarters · filed 2024-03-25 | $227.26K 10-K · filed 2024-03-25 | ||
| 2022-09-30 | $60.34K 10-Q · filed 2022-11-10 | $86.26K derived: sum of 2 quarters · filed 2023-08-11 | $123.08K 10-Q · filed 2022-11-10 | $144.68K derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2022-06-30 | $25.92K 10-Q · filed 2023-08-11 | $62.74K 10-Q · filed 2023-08-11 | $84.34K derived: sum of 3 quarters · filed 2023-08-11 | $108.96K derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2022-03-31 | $36.83K 10-Q · filed 2023-05-12 | $58.42K derived: sum of 2 quarters · filed 2023-05-12 | $83.04K derived: sum of 3 quarters · filed 2023-05-12 | $128.75K derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $21.60K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $46.22K derived: sum of 2 quarters · filed 2023-03-24 | $91.92K derived: sum of 3 quarters · filed 2023-03-24 | $162.95K 10-K · filed 2023-03-24 | ||
| 2021-09-30 | $24.62K 10-Q · filed 2022-11-10 | $70.32K derived: sum of 2 quarters · filed 2022-11-10 | $141.35K 10-Q · filed 2022-11-10 | $157.78K derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $45.71K 10-Q · filed 2022-08-01 | $89.37K 10-Q · filed 2021-08-13 | $116.73K 10-Q · filed 2022-08-01 | $179.76K 10-Q · filed 2021-08-13 | $133.16K derived: sum of 3 quarters · filed 2022-08-01 | $140.76K derived: sum of 4 quarters · filed 2022-08-01 |
| 2021-03-31 | $71.03K 10-Q · filed 2022-05-13 | $90.39K 10-Q · filed 2021-05-17 | $87.46K derived: sum of 2 quarters · filed 2022-05-13 | $95.06K derived: sum of 3 quarters · filed 2022-05-13 | $125.71K derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | $16.43K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $24.03K derived: sum of 2 quarters · filed 2022-03-28 | $54.68K derived: sum of 3 quarters · filed 2022-03-28 | $50.19K 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $7.60K 10-Q · filed 2021-11-10 | $38.25K derived: sum of 2 quarters · filed 2021-11-10 | $33.76K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $30.65K 10-Q · filed 2021-08-13 | $47.69K 10-Q · filed 2021-08-13 | ||||
| 2020-03-31 | $17.04K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |